Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 3/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9685278 | 0.91 | KMT2A (0.40) | CFTRNR4A2CDK1CCNB2CCNB1 | |
| Hydrochloric Acid SCHEMBL10701881 | 0.90 | KMT2A (0.39) | CFTRNR4A2LMNACDK1CCNB2 | |
| SCHEMBL2706382 | 0.87 | MAPKAPK2 (0.44) | SIRT1MAPKAPK2OPRM1OGFRL1 | |
| SCHEMBL2780429 | 0.86 | MAPKAPK2 (0.45) | CFTRBAZ2BMAPTSIRT1LMNA | |
| SCHEMBL2706845 | 0.86 | MAPKAPK2 (0.52) | CFTRMAPTALDH1A1LMNAMAPKAPK2 | |
| SCHEMBL10465435 | 0.84 | KMT2A (0.43) | CFTRALDH1A1LMNAMAPK1GSK3B | |
| SCHEMBL6238822 | 0.83 | KMT2A (0.51) | MAPTALDH1A1LMNAOPRM1OGFRL1 | |
| SCHEMBL11458021 | 0.79 | KMT2A (0.54) | CFTRMAPTPOLBALDH1A1LMNA | |
| SCHEMBL9687547 | 0.79 | KMT2A (0.45) | CFTRMAPTMAPK1GSK3BCDK5 | |
| SCHEMBL2708913 | 0.78 | MAPKAPK2 (0.55) | CFTRMAPTALDH1A1LMNAMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | claimed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | claimed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351964-B2 | Methods for treating cancer and non-neoplastic conditions | PTC THERAPEUTICS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| WO-2011150162-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010138695-A1 | METHODS FOR TREATING NEUROFIBROMATOSIS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138659-A1 | METHODS FOR TREATING BRAIN TUMORS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138706-A1 | METHODS FOR TREATING BREAST CANCER | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138685-A1 | METHODS FOR TREATING PROSTATE CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138758-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138652-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-0891187-B1 | USE OF DERIVATIVES OF TETRAHYDRO-BETA-CARBOLINES AS ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | disclosed |
| US-6069150-A | METALLOPROTRINASE INHIBITOR | F. HOFFMAN-LA ROCHE AG (CH) | 2000-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | CFTR 4296/4885BAZ2B 1885/4885MAPT 3300/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | CFTR 4302/4885BAZ2B 1903/4885MAPT 3328/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | CFTR 4302/4885BAZ2B 1903/4885MAPT 3328/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | CFTR 4309/4885BAZ2B 856/4885MAPT 2964/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | CFTR 4007/4885BAZ2B 606/4885MAPT 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.